November 15, 2022
The chief of research and immunotherapy at Cedars-Sinai The Angeles Clinic and Research Institute discussed updated data from the phase 2 C-144-01 study of the lifileucel TIL therapy.
January 30, 2022
The director of the Melanoma Program at Cedars-Sinai Medical Center discussed the efficacy of TIL therapy following immunotherapy in advanced melanoma.
January 27, 2022
The director of the Melanoma Program at Cedars-Sinai Medical Center discussed evaluation criteria for TIL therapy in melanoma.